Penn Research Finds Psoriasis Medication Apremilast Leads to Fat Loss in People with Psoriasis

Apremilast (brand name Otezla) has helped psoriasis patients achieve clearer skin and ease the symptoms of their psoriatic arthritis. Now, new data from researchers at the Perelman School of Medicine at the University of Pennsylvania shows it could also help people with psoriasis shed unhealthy body fat and therefore improve cardiovascular health, a well-known vulnerability for those with psoriasis.

Researchers Uncover Link Between Racial, Ethnic and Socioeconomic Factors and Likelihood of Getting Effective Treatment for Atrial Fibrillation

Even though the use of rhythm control strategies for treating Paroxysmal Atrial Fibrillation (AF), a common abnormal heart rhythm, have increased overall in the United States, patients from racial and ethnic minority groups and those with lower income were less likely to receive rhythm control treatment – often the preferred treatment – according to new research from the Perelman School of Medicine at the University of Pennsylvania.

Patients on a Low-Calorie Diet along with Intensive Behavioral Therapy Lost Nearly Three Times as Much Weight When Taking New Anti-Obesity Medication, Semaglutide, than When Taking Placebo

A second study of the injectable anti-obesity medication, semaglutide, has confirmed the large weight losses reported in a study earlier this month, establishing the reliability and robustness of this new drug. With obesity affecting more than 40 percent of American adults, the findings could have a major impact on weight management in primary care and other settings.